Chemical structure
Cat.No.
Product Name
CAS no.
Target
YN440429 6-Demethoxytangeretin 6601-66-7
6-Demethoxytangeretin is a citrus flavonoid isolated fromCitrus depressa. 6-Demethoxytangeretin exerts anti-inflammatory activity and anti-allergic activity, suppresses production and gene expression of interleukin-6 in human mast ce...
YN440313 ALK inhibitor 1 761436-81-1
ALK inhibitor 1 (compound 17) is a potent pyrimidinALKinhibitor. ALK inhibitor 1 is a potent inhibitor oftestis-specific serine/threonine kinase 2(TSSK2;IC50=31nM) and focal adhesion kinase(FAK;IC50=2nM).
YN440314 ALK inhibitor 2 761438-38-4
ALK inhibitor 2 (compound 18) is a potent pyrimidinALKinhibitor. ALK inhibitor 2 is a potent inhibitor oftestis-specific serine/threonine kinase 2(TSSK2;IC50=37nM) and focal adhesion kinase(FAK;IC50=5nM).
YN440051 NVP-TAE 684 761439-42-3
TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
YN440407 Crizotinib 877399-52-5
Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
A 83-01 is a potent inhibitor of TGF-β type I receptorALK5 kinase, type I nodal receptorALK4 and type I nodal receptorALK7, with IC50s of 12nM, 45nM and 7.5nM against the transcription induced byALK5,ALK4 and ...
YN440335 Ceritinib 1032900-25-6
Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.
ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.
YN440240 GSK1838705A 1116235-97-2
GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.
YN440226 Brigatinib 1197953-54-0
Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.
YN440273 ALK-IN-1 1197958-12-5
AP26113-analog (ALK-IN-1) is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.
YN440237 Alectinib 1256580-46-7
Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.
YN440238 Alectinib Hydrochloride 1256589-74-8
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.
YN440334 AZD-3463 1356962-20-3
AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.
YN440348 HG-14-10-04 1356962-34-9
HG-14-10-04 is an inhibitor of ALK .
X-376 is an ALK inhibitor and potentially useful in non-small cell lung cancer.
YN440336 Ceritinib dihydrochloride 1380575-43-8
Ceritinib (Zykadia, LDK378) dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK with IC50 of 0.2 nM. Ceritinib dihydrochloride also inhibits InsR, IGF-1R and ...
YN440350 CEP-37440 1391712-60-9
CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3nM (FAK) and 120nM(ALK cellular IC50 in 75% human plasma). Preparation of fused bicyclic 2,4-diaminopyrimidine derivatives as a du...
YN440408 Crizotinib hydrochloride 1415560-69-8
Crizotinib (PF-02341066) hydrochloride (Xalkori) inhibits tyrosine phosphorylation of c-Met and nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) with IC50 of of 11 nM and 24 nM in cell...
YN440198 Lorlatinib 1454846-35-5
PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. Phase 1.
TELL : +86-020-82000279
Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.
